Tang Capital Management adds aTyr Pharma Inc (LIFE) to its portfolio

aTyr Pharma Inc (LIFE) : Tang Capital Management added new position in aTyr Pharma Inc during the most recent quarter end. The investment management firm now holds 190,000 shares of aTyr Pharma Inc which is valued at $649,800 , the company said in a statement filed on Aug 15, 2016 with the SEC.aTyr Pharma Inc makes up approximately 0.33% of Tang Capital Management’s portfolio.

Other Hedge Funds, Including , Ecor1 Capital sold out all of its stake in LIFE during the most recent quarter. The investment firm sold 74,959 shares of LIFE which is valued $256,360. Norges Bank sold out all of its stake in LIFE during the most recent quarter. The investment firm sold 10,000 shares of LIFE which is valued $34,200. Alambic Investment Management sold out all of its stake in LIFE during the most recent quarter. The investment firm sold 60,396 shares of LIFE which is valued $194,475. Strs Ohio sold out all of its stake in LIFE during the most recent quarter. The investment firm sold 1,900 shares of LIFE which is valued $5,890. Acadian Asset Management added LIFE to its portfolio by purchasing 1,460 company shares during the most recent quarter which is valued at $4,468.

aTyr Pharma Inc opened for trading at $2.91 and hit $2.99 on the upside on Thursday, eventually ending the session at $2.95, with a gain of 1.03% or 0.03 points. The heightened volatility saw the trading volume jump to 93,665 shares. Company has a market cap of $70 M.

aTyr Pharma Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe rare diseases using a set of physiological modulators. The Company has discovered approximately 300 Physiocrines a class of naturally occurring proteins that promotes homeostasis. The Company’s Physiocrines have therapeutic application in various diseases characterized by tissue dysfunction including severe diseases of the lung gut skin brain and liver. The Company is engaged the development of Resolaris as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component or RMICs. The Company has developed Resolaris based on its discovery of the Resokine pathway in skeletal muscle tissue an extracellular pathway in human skeletal muscle tissue associated with activities arising from various Physiocrine regions of the human histidine aminoacyl tRNA synthetase.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *